PFSA logo

PROFUSA INC

PFSANASDAQ
🏆 #5362 by market capUS Equity
$590.20▲ $32.70 (+5.54%)
Simulated price
🔔
Track PFSA
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 5.5%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$2M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
56
Weak
No chart data available for PFSA.

Trading Snapshot

Day Range
$587.34 – $597.95
52-Week Range
$1.58 – $3,000.00
Volume
$3.18B
Avg Volume
$2.44B
Shares Outstanding
1.1M
Next Earnings
Nov 26, 2026

Fundamentals Snapshot

Annual Revenue
$141,162
Last Q Revenue
$36,758
P/E Ratio
-0.0
P/S Ratio
0.0x
EPS (TTM)
$-745.02
Dividend Yield
0.00%
Dilution (1yr)
+4667.4%

Why Investors Own PFSA

  • ✓High-growth profile — revenue up +12.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 36% gross margin and 20% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PFSA logo

PROFUSA INC

PFSA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$13M▲ +193.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$16M▲ +686.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.2M▲ +4667.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$13M▼ −$4M YoY
StockOtter · stockotter.space

About PROFUSA INC

Profusa, Inc. is a pioneering health technology firm that engineers advanced, bio-integrated sensors. These innovative devices, exemplified by their Lumee™ Oxygen Platform, are designed for uninterrupted observation of internal physiological markers. By leveraging artificial intelligence, Profusa translates this constant stream of data into actionable health insights, primarily to empower individuals and clinicians in the management of persistent health challenges like diabetes and critical limb ischemia.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Price Target

ⓘ
Average Target
$611.30
▲ +3.6% Upside
High Target$736.78
Low Target$479.35
Based on 34 analysts

Latest News & Updates

🚀
Reuters·2h ago

PROFUSA INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift PFSA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

PROFUSA INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.